Withdrawn study: brain zaps for schizophrenia never tested
NCT ID NCT06142422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a type of brain stimulation called intermittent theta burst stimulation on the precuneus area in people with resistant schizophrenia who had experienced childhood trauma. The goal was to see if it could reduce symptoms better than a placebo. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- stimulation device
- What could go wrong
- The study was withdrawn before enrolling any participants, so no data were collected. It is unknown if this approach would be safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Right-handed patient aged 18 to 40 years inclusive; * Patient presenting schizophrenia as defined in the Diagnostic and Statistical Manual-5; * Patient under antipsychotic treatment in accordance with the recommendations of the High Authority of Health, at a stable dosage and without modification of psychotherapeutic treatment for at least 4 weeks; * Patient on mono or dual antipsychotic therapy. * Patient presenting residual symptoms, i.e. absence of remission defined by the criteria of the "Remission criteria of the Schizophrenia Working Group Consensus"; * Patient having been exposed to at least one type of trauma in childhood and having a score higher than the threshold values of the childhood trauma questionnaire: emotional neglect, physical abuse, emotional abuse, physical neglect, sexual abuse; * Patient having signed an informed consent form to participate in the study. Exclusion Criteria: * Patient with a contraindication to magnetic resonance imaging or intermittent Theta Burst Stimulation (presence of a metallic body, pacemaker, implantable defibrillator or other implantable metallic device, epilepsy, stroke or recent head trauma); * Patient who is not French-speaking or cannot read and write; * Patient under guardianship; * Patient in forced care (psychiatric care upon decision of the State representative and psychiatric care at the request of a third party); * Pregnant woman or likely to be pregnant (of childbearing age) without effective contraception or breastfeeding; * Patient participating in another clinical trial, or during a period of exclusion from another clinical trial; * Patient who is not a beneficiary of a social security system. * Patient who, according to the assessment of the investigator, risks not being compliant or diligent in the study procedures.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinique Rech
Montpellier, 34093, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia